1. Introduction {#S1}
===============

We found that transgenic mice constitutively over-expressing ARID3a in all B lymphocytes produced anti-nuclear antibodies by four weeks of age, and on multiple genetic backgrounds \[[@R1],[@R2]\]. These data linked ARID3a expression with autoimmunity and the generation of autoantibodies. In those mice, expanded numbers of MZ B cells were observed, and autoantibody production was correlated with numbers of MZ cells in chimeric mice \[[@R2]\]. Together, these data suggest a role for ARID3a in innate antibody production and autoimmunity.

Recently, we performed cross-sectional and longitudinal studies of systemic lupus erythematosus (SLE) patients to determine if ARID3a is over-expressed in human autoimmune disease \[[@R3]\]. Those studies revealed that 43% of SLE patients have expanded ARID3a^+^ B cells, and that total numbers of ARID3a^+^ B cells were associated with increased disease activity in individual patients assessed at different time points. In healthy individuals, ARID3a expression was restricted to B cell differentiation stages that typically comprise less than 10% of peripheral blood B cells \[[@R3]\]. However, in SLE patients, we observed ARID3a expression at all stages of B cell development, including the naïve B stage, which showed very few ARID3a^+^ B cells in healthy individuals. In some patients, numbers of circulating ARID3a^+^ B cells were increased as much as 100-fold. Due to differences in surface markers used to define innate B cells in mice versus humans, it was difficult to discern in that study if ARID3a expression preferentially occurred in innate B cells in man, as in mice. However, we observed elevated numbers of ARID3a^+^ cells within the previously defined innate-like MZ memory (IgD^+^IgM^+^CD27^+^) \[[@R4]\] B cell population in SLE samples. Intriguingly, numbers of ARID3a^+^ B cells within this subset most highly correlated with disease activity, consistent with the hypothesis that these antibodies might be autoreactive. Therefore, we hypothesized that ARID3a^+^ naïve B cells present in lupus patients, but not in healthy controls, might be precursors of this innate B cell population, and that they would preferentially produce autoreactive immunoglobulins.

To test this hypothesis, we generated monoclonal antibodies from SLE patient samples with high and normal ARID3a expression and sequenced the immunoglobulin heavy and light chains to determine the CDR3 and junctional sequences. Furthermore, we evaluated these antibodies by several methods for autoreactivity and reactivity with multiple SLE-associated autoantigens.

2. Results and Discussion {#S2}
=========================

Previous studies indicated that SLE patients with numbers of ARID3a^+^ B cells more than two standard deviations above the mean numbers found in healthy controls (ARID3a^H^, high samples) had increased disease activity relative to patient samples with normal numbers of ARID3a^+^ B cells (ARID3a^N^, normal samples) \[[@R3]\]. In addition, while division of SLE patient samples based on ARID3a expression allowed segregation of patients into groups roughly correlated with low and high disease activity, these two groups also differed in total serum Ig and IL10 levels \[[@R3]\]. Therefore, we predicted segregation of patient samples based on ARID3a expression would reveal mechanistic clues to the association between ARID3a expression and disease activity.

Others have shown autoreactivity in the naïve B population as a breakdown of a tolerance checkpoint, and that 25%--50% autoreactive cells were present in naïve B cells from SLE patients \[[@R5]\]. Because ARID3a^H^ patient samples showed ARID3a expression in 40X more naïve B cells on average, B cells that do not normally express ARID3a in healthy controls, we hypothesized that those cells might represent expansions of autoreactive B cells that would eventually break tolerance. Therefore, we chose to analyze antibodies from SLE naïve B cells for our experiments.

ARID3a expression was determined in SLE patient B cells via staining of peripheral blood mononuclear cells (PBMCs), gating on CD19^+^ B cells by flow cytometry, and defining samples as ARID3a^H^ if the concentration of ARID3a^+^ B cells/mL was \>2 standard deviations above the average of concentration of ARID3a^+^ B cells/mL (9800 ARID3a^+^ cells/mL) in healthy control peripheral blood, while other samples were characterized as ARID3a^N^, as previously described \[[@R3]\]. Naïve B cells from a representative ARID3a^N^ sample with 3.7% ARID3a^+^ naïve B cells, and a representative ARID3a^H^ sample with 9.5% ARID3a^+^ naïve B cells were single-cell sorted into 96-well plates, using B lymphocyte (CD19^+^) and naïve B cell (IgM^+^IgD^+^CD27^−^CD10^−^) surface markers. The total percentage of ARID3a^+^ cells was 2.5 times greater in ARID3a^H^ versus ARID3a^N^ in the naïve B cell population.

Immunoglobulin gene origins and specificities associated with ARID3a expression have not been previously evaluated in human naïve B cells. To determine if SLE naïve B cells, enriched in ARID3a expression, show differential usage of V, D, and J genes in ARID3a^H^ versus ARID3a^N^ naïve B cells, heavy and light chains of single cells sorted from the naïve B cell subset were amplified via reverse transcription polymerase chain reaction (RT-PCR) and sequenced. Of the 48 immunoglobulin variable heavy chain (VH) genes, sequenced from ARID3a^H^ naïve B cells, we observed a dominance of immunoglobulin heavy chain (IgH) V3 family (71%) genes ([Figure 1](#F1){ref-type="fig"}). Although the VH3 family was also dominantly expressed in ARID3a^N^ naïve B cells (54%), from which sequences were obtained, the VH4 family was preferentially observed in ARID3a^N^ versus ARID3a^H^ antibodies ([Figure 1](#F1){ref-type="fig"}). Each of the other four human VH gene families observed were similarly expressed between the two samples.

Further analyses revealed that individual VH genes within the four gene families were expressed at different proportions in cells obtained from ARID3a^H^ versus ARID3a^N^ naïve B cell samples ([Figure 2](#F2){ref-type="fig"}). IGHV3-30 and IGHV3-23 were the most highly expressed genes in both sample sets, but each sample set contained VH genes not found in the other. There were more VH genes exclusively expressed by the ARID3a^N^ cells (n = 9), including members of the VH4 family, as compared to ARID3a^H^ cells (n = 6), which showed exclusive expression of several VH3 genes. Together, these data suggest there may be VH gene bias in the ARID3a^H^ naïve B cells toward VH3 sequences; although, a larger sample size is needed to indicate statistical significance (p = 0.11, chi-squared).

Previously, we determined that ARID3a binds only a subset of murine and human immunoglobulin heavy chain promoters \[[@R6]\]. Interestingly, the prototype binding site in the mouse was identified in the V1 gene of the VHS107 family, the murine equivalent of the human IgH V3 family \[[@R7]\]. Therefore, it may not be surprising that ARID3a^H^ naïve B cells showed increased usage of the VH3 family ([Figure 1](#F1){ref-type="fig"}). We did not see a dramatic difference between ARID3a^H^ and ARID3a^N^ naïve B cell samples in usage of the mouse V1 human equivalent, IGHV3-23 ([Figure 2](#F2){ref-type="fig"}) \[[@R8]\]; although, in earlier studies we showed that expression of the V1 gene was enhanced by ARID3a.

Each antibody sequence was further analyzed to determine use of the 23 functional human diversity (DH) and six joining (JH) gene segments. Usage varied considerably between the two sample sets ([Figure 3A](#F3){ref-type="fig"}). While approximately half of the ARID3a^N^ naïve cell-derived antibodies utilized D3 sequences, ARID3a^H^ naïve B cells had notably higher frequencies of D2 and D5 sequences. D gene families, with the exception of D7, were more evenly represented in ARID3a^H^ naïve B cells. Monoclonal antibodies from ARID3a^H^ naïve B cells revealed preference for the JH4 gene segment ([Figure 3B](#F3){ref-type="fig"}), without usage of JH1. In turn, ARID3a^H^ naïve B cells preferentially used JH3 and JH4 gene segments. Although some differences in expression occurred in both DH and JH gene segments from ARID3a^H^ versus ARID3a^N^ antibodies in these relatively small samples, each sample expressed multiple heavy chain gene segments.

We also analyzed light chain usage of each single-sorted naïve B cell; although, ARID3a has not been shown to modulate light chain gene expression \[[@R6]\]. Multiple different Ig kappa variable (Vκ) gene segments were expressed in each sample set. Strikingly, the IGKV1-39 gene showed increased use in ARID3a^N^ compared to ARID3a^H^ naïve B cells ([Figure 4](#F4){ref-type="fig"}). As a whole, numbers of expressed Vκ genes were more diversified in ARID3a^H^ naïve B cells, with expression of seven genes not found in ARID3a^N^ samples. Vκ joining gene use was similar between the two sample sets; although nearly 40% of the ARID3a^H^ cells expressed IGKJ1 ([Figure 5](#F5){ref-type="fig"}). These data suggest that Ig kappa light chains are diversely expressed in ARID3a^H^ and ARID3a^N^ naïve SLE B cells.

To determine if antibodies generated from ARID3a^H^ SLE cells were more likely to be autoreactive than antibodies from ARID3a^N^ SLE cells, the IgH and Igκ chains expressed in 15 ARID3a^N^ and 16 ARID3a^H^ single-sorted naïve B cells were amplified via RT-PCR, and expressed as monoclonal IgG antibodies \[[@R9]\]. A summary of IgH V, D, and J gene origins for each ARID3a^N^ and ARID3a^H^ monoclonal antibody is presented in [Table 1](#T1){ref-type="table"}. Reactivity against nuclear antigens was assessed with a common ANA test using human epithelial 2 (Hep-2) cells \[[@R10]\]. Representative results for an ARID3a^H^ and an ARID3a^N^ monoclonal antibody are shown in [Figure 6A](#F6){ref-type="fig"}. Multiple types of ANA nuclear staining patterns were observed in both ARID3a^H^ and ARID3a^N^ antibodies, and included homogeneous and nucleolar staining (bottom right, [Figure 6A](#F6){ref-type="fig"}), with and without cytoplasmic reactivity. Contrary to our prediction, slightly more monoclonal antibodies generated from ARID3a^N^ (n = 6/16, 38%) naïve B cells were ANA^+^, versus those generated from the ARID3a^H^ naïve B cells (n = 4/15, 27%) ([Figure 6B](#F6){ref-type="fig"}). Based on this initial small sample size, we expected to see 0 ANA^+^ antibodies from the ARID3a^N^ sample and only 1--2 ANA^+^ antibodies from the ARID3a^H^ sample if ARID3a expression was associated with ANA activity. Indeed, statistical evaluation of our data using a standard Z test indicates that the likelihood that ARID3a expression could be used as a marker of autoreactive B lymphocytes is \<0.01% (p \< 0.0001) in the ARID3a^N^ sample, and \<2.5% (p \< 0.025) in the ARID3a^H^ sample- where nearly 10% of the cells expressed ARID3a. Others have shown that autoantibodies can be made in healthy individuals and in patients prior to diagnosis with SLE \[[@R5],[@R11],[@R12]\], and the percentages of autoantibodies we observed in both patient samples (27%--38%) were similar to those observed by others \[[@R5]\]. Therefore, in spite of our previous findings that increased numbers of ARID3a expressing cells correlated with increased disease activity, our data suggest that ARID3a expression is not correlated with generation of autoreactive antibodies in naïve B cells.

In the mouse, ARID3a expression preferentially led to the development of MZ B cells that generate polyreactive IgM antibodies, rather than follicular B cells \[[@R12],[@R13]\]. Therefore, we hypothesized that antibodies from ARID3a^H^ samples may be more likely to have characteristics of polyreactive versus monospecific antibodies, despite the lack of association with autoreactivity. The complementarity determining region 3 (CDR3) of the IgH shows the highest degree of variability in IgH sequences, and longer amino acid loops in this region of the antigen binding site are thought to confer nonspecific binding to multiple epitopes as is observed with polyreactive antibodies \[[@R12],[@R14]\]. Therefore, we determined the length of the CDR3 region in each of our monoclonal antibodies to determine if antibodies generated from ARID3a^H^ naïve B cell samples had longer CDR3-regions versus ARID3a^N^ CDR3s. CDR3s are listed in [Table 2](#T2){ref-type="table"}. We did not observe a significant difference in the average number of amino acids (aa) in CDR3 regions between ARID3a^H^ (13.73) versus ARID3a^N^ (13.81). Further, there were ANA^+^ monoclonals with short (\<10 aa) CDR-H3s that were ANA^+^, and some with longer (\>15 aa) CDR3s that did not react against nuclear antigens ([Table 2](#T2){ref-type="table"}). Together, these data indicate that CDR3 length did not correlate with autoreactivity or with ARID3a expression in this study.

Increases in positively charged amino acids in CDR3-regions have been associated with anti-DNA antibodies in autoimmune disease \[[@R15]\]. The sugar-phosphate backbone of DNA lends an overall negative charge to DNA; therefore, increases in numbers of positively charged amino acids in the antigen-binding site of an antibody augment affinity for DNA. Therefore, we determined if ANA^+^ ARID3a^H^ monoclonal antibodies had increased numbers of the positively charged amino acids, lysine (K), arginine (R), and histidine (H), within the CDR3. However, there were no significant differences in the mean average of positively charged amino acids in the CDR3 regions of antibodies from either sample ([Table 2](#T2){ref-type="table"}). ANA^+^ antibodies from ARID3a^H^ naïve B cells had 1 or 2 positively charged amino acids, while two ANA^+^ antibodies from ARID3a^N^ naïve B cells had three positive charges in CDR-H3. These data suggest that ARID3a expression did not correlate with longer CDR-H3 regions, or increased use of positively charged amino acids in this study.

Because our data suggested that segregation of patient samples based on ARID3a expression identified phenotypic differences that were related to disease activity \[[@R3]\], we asked if antibodies generated from the sample with increased ARID3a expression preferentially reacted with specific SLE-associated antigens. Therefore, we further examined the specificities of all ANA^+^ monoclonal antibodies using bead (*i.e*., Bioplex 2200), Western blot (*i.e*., INNO-LIA), and indirect immunofluorescence (*i.e*., *Crithidia luciliae*) based systems (reviewed in \[[@R16]\]). A Bio-Rad BioPlex 2200 panel containing multiple SLE-associated antigens (e.g., Sm, RNP, and DNA), and a few more antigen reactivities commonly observed in systemic sclerosis or inflammatory myositis (topoisomerase 1 \[Scl-70\], centromere B, and Jo-1) \[[@R17]\], showed that one of the ARID3a^H^ ANA^+^ antibodies was polyreactive against several antigens, including Sm/RNP, Centromere B, Scl-70, Ribosomal P, and chromatin ([Table 3](#T3){ref-type="table"}). However, none of the other antibodies reacted with any of the antigens tested in this assay. Using a similar ANA panel, with the addition of histones, the antibodies were further tested for ANA reactivities using INNO-LIA^TM^ ([Figure 7](#F7){ref-type="fig"}). The same ARID3a^H^ antibody (g03) that showed polyreactivity on the BioPlex assay ([Table 3](#T3){ref-type="table"}), tested positive against all similar antigens in the INNO-LIA^TM^ ANA panel ([Figure 7](#F7){ref-type="fig"}). In addition, ARID3a^H^ antibody (g06) also demonstrated reactivity against RNP-A and histones ([Figure 7](#F7){ref-type="fig"}), indicating polyreactivity. Only one of the ARID3a^N^ antibodies (a04) showed reactivity in the specificity testing, binding histones (a04) in the INNO-LIA^TM^ ANA panel ([Figure 7](#F7){ref-type="fig"}), and showed reactivity against dsDNA via *Crithidia luciliae*. Therefore, in this small sample size cloned from individual naïve B cells, we did not observe skewing toward any specific antigen reactivity. This is consistent with our previous findings suggesting no obvious correlation between antibody reactivity and ARID3a expression in measurements obtained from whole plasma \[[@R3]\].

Although others have made monoclonals from various peripheral blood B cell subsets of SLE patients and compared them to those found in healthy control peripheral blood \[[@R5]\], our data are the first to be able to subset SLE patient samples according to disease activity based on ARID3a expression. In previous work \[[@R3]\], we found that segregation of SLE patient samples based on high or normal ARID3a expression showed significant differences in total circulating Ig and IL10, despite the fact that differences were not apparent when total SLE samples were compared to healthy controls. While our previous studies showed increased circulating Ig in ARID3a^H^ versus ARID3a^N^ plasma samples, total numbers of ARID3a^+^ B cells (most of which do not secrete antibody) were not correlated with ANA levels \[[@R3]\]. Our new single cell analyses now suggest that ARID3a expression in naïve B cells is not correlated with the generation of ANA producing B cells at the single cell level. Therefore, correlations between increased disease activity and numbers of ARID3a^+^ B cells are unlikely to be due to ARID3a effects on antibody-mediated processes. Rather, increased disease activity in association with ARID3a expression is likely mediated by antibody-independent processes.

3. Experimental Section {#S3}
=======================

Participants {#S4}
------------

SLE patients who met a minimum of four American College of Rheumatology Classification Criteria for SLE \[[@R18]\] were recruited after informed consent from the Oklahoma Medical Research Foundation (OMRF) (IRB compliance \#09-07 and \#06-19), in accordance with the Declaration of Helsinki. For these studies, heparinized peripheral blood was collected from two female patients, ages 41 and 43, characterized as having high or normal numbers of ARID3a-expressing B lymphocytes at the time of draw, and was used as described further below.

Flow Cytometry {#S5}
--------------

Mononuclear cells were isolated from heparinized peripheral blood (\~15 mL) with Ficoll-Paque Plus (GE Healthcare) and counted. The majority of the cells were retained for molecular analyses, and approximately 10% of the PBMCs were stained with the following fluorochrome-labeled antibodies: CD19 PE-Cy5, CD10 Pacific Blue (BioLegend), IgD PerCP-Cy5.5, CD27 PE-Cy7, and IgM APC (Southern Biotech) or isotype controls. Cells were fixed with 2% paraformaldehyde, permeabilized with 0.1% Tween-20 and stained with goat anti-human ARID3a antibody \[[@R14]\] followed by rabbit anti-goat IgG FITC (Invitrogen). Gating for individual B cell subsets was as described previously \[[@R3]\]. Appropriate isotype controls (Caltag, BD Pharmingen, and eBioscience) used for gating individual B cell subsets were described previously \[[@R3]\]. Data (500,000 events per sample) were collected using an LSRII (BD Biogenics) and FACSDiva (BD Biosciences) software version 4.1 and were analyzed using CellQuest Pro (BD Biosciences) and FlowJo (Tree Star) software versions 6.0 and 9.5.2, respectively. Samples with more than 9830 total ARID3a^+^ B cells/mL (\>2 standard deviations above the average numbers of ARID3a^+^ B cells observed in healthy control B cells) were designated as ARID3a^H^, while those with fewer than 9830 ARID3a^+^ B cells/mL were designated ARID3a^N^, as we defined previously \[[@R3]\].

Generation of Monoclonal Antibodies {#S6}
-----------------------------------

The remaining peripheral blood mononuclear cells were B cell-enriched by negative selection via magnetic bead separation (StemCell Technologies) and stained for flow cytometry to identify naïve B cells (CD19^+^IgD^+^IgM^+^CD27^−^CD10^−^) for sequence analyses. These cells were first bulk-sorted using a Becton-Dickinson FACS Aria flow cytometer, then single-cell sorted into 96-well plates with 10 μL of catch buffer /well (10 mM Tris-HCL with 40 U/μL RNAse inhibitor (Promega) using a Cytomation MoFlo cytometer. After sorting, the plates were put on dry ice and stored at −80 °C until reverse transcription, sequencing, and generation of monoclonal antibodies by the OMRF Antibody Core Facility, as described previously \[[@R19]--[@R21]\]. Briefly, IGHV and IGKV regions were amplified using a One-Step RT-PCR kit (Qiagen, Valencia, CA, USA) with a cocktail of sense primers to leader regions of each gene family and antisense primers to the constant regions of the heavy and kappa chains \[[@R9],[@R12]\]. One 3L of the RT-PCR mixture was amplified in separate heavy and kappa chain PCR reactions for sequencing, or used in another PCR reaction, incorporating restriction sites for further cloning into expression vectors with full length IgG1 heavy or kappa constant regions. Heavy and light chain plasmids from individual cells were co-transfected into the HEK293A cell line using polyethyleneimine (PEI) (Polysciences, Warrington, PA, USA), and were cultured for five days in serum-free DMEM supplemented with 1% Nutridoma (Roche, Indianapolis, IN, USA). Secreted antibodies were purified using protein A-agarose beads (Pierce, Rockford, IL, USA). Antibody concentrations were determined using a Nanodrop spectrophotometer (Fisher, Pittsburg, PA, USA), and checked for purity and integrity by SDS-PAGE.

Sequence Analyses {#S7}
-----------------

Variable region sequences were analyzed using the International Immunogenetics Information System (IMGT, Montpellier, France, \[[@R22]\]), as well as with in-house software and/or Vector NTI (Invitrogen, Carlsbad, CA, USA). CDR positions were determined by IMGT.

Antigen Reactivity Assessments {#S8}
------------------------------

Monoclonal antibodies (50--100 μg/mL) \[[@R5]\] were tested for reactivity against nuclear antigens using indirect immunofluorescence staining of human epithelial-2 cells (Hep-2 complete kit, Bio-Rad), following the manufacturer's protocol. Briefly, monoclonal antibodies (50--100 μg/mL) were incubated with Hep-2 cells, and detected utilizing a fluorescein isothiocyanate (FITC) secondary antibody. Nuclear antigen reactivities and staining pattern classifications were determined visually with immunofluorescent microscopy. ANA nuclear staining pattern categories were: Nuclear Homogeneous, Nuclear Speckled, Cytoplasmic, and Centromere/Nucleolar. Antibody specificities were determined using an ANA screen (Bio Rad) for the BioPlex^TM^ 2200, and INNO-LIA^TM^ ANA Update test strips (Innogenetics). Doubled-stranded DNA (dsDNA) was detected with the NOVA Lite® dsDNA *Crithidia luciliae* kit (Inovadx), following manufacturer's protocols, and interpreted blindly by Cathy Velte, Manager of the OMRF Clinical Immunology Laboratory, which is a CAP-certified testing reference laboratory.

4. Conclusions {#S9}
==============

We previously found that numbers of ARID3a^+^ B cells were dramatically increased in SLE patients compared to healthy controls, and that numbers of ARID3a^+^ B cells in those patients were associated with increased disease activity \[[@R3]\]. Because ARID3a^+^ naïve B cells are not generally detected in healthy individuals, we hypothesized that antibodies from those naïve cells would be predisposed to interact with nuclear antigens as observed in SLE. In this study, we did not find increased autoreactivity in the monoclonal antibodies generated from ARID3a^H^ versus ARID3a^N^ naïve B cell samples. Indeed, our data show there is no correlation between ARID3a expression and autoantibody production. Numbers of ARID3a^+^ cells were associated with disease activity in our previous longitudinal study; therefore, it will be important to determine how these cells contribute to inflammatory processes in SLE patients. Our data suggest that increased disease activity in patients with high numbers of ARID3a^+^ naïve B cells is due to an antibody-independent mechanism, rather than increases in autoreactive antibodies.
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![ARID3a^H^ and ARID3a^N^ SLE naïve B cells showed greater usage of IGHV3 family genes. Pie charts indicate total numbers of immunoglobulin V gene sequences (37 and 48) amplified via qRT-PCR and sequenced from single naïve B cells obtained from ARID3a^N^ *versus* ARID3a^H^ samples. Percentages of antibodies encoded by IGHV genes from each of the four families are indicated.](nihms826709f1){#F1}

![SLE naïve B cells showed differential usage of immunoglobulin heavy chain variable genes. Percentages of individual IgH V genes in sequences obtained from ARID3a^N^ (n = 37) and ARID3a^H^ (n = 48) single naïve B cells.](nihms826709f2){#F2}

![ARID3a^H^ and ARID3a^N^ SLE naïve B cells showed differential usage of IGHD and IGHJ gene segments. (**A**) The bar graph indicates percentages of IgH D or (**B**) IgH J gene segments obtained from sequencing single naïve B cells from ARID3a^N^ (n = 37) and ARID3a^H^ (n = 48) SLE samples.](nihms826709f3){#F3}

![Use of Ig Kappa Variable (IGKV) region genes were more diversified in ARID3a^H^ than in ARID3a^N^ naïve B cells. Percentages of Ig Vκ gene sequences from individual 37 ARID3a^N^ and 48 ARID3a^H^ single naïve B cells are shown.](nihms826709f4){#F4}

![Use of immunoglobulin kappa chain joining Jκ 1--5 gene segments were similar between ARID3a^H^ and ARID3a^N^ naïve B cell samples. Percentages of light chain Jκ gene segment sequences from 37 individual ARID3a^N^ and 48 ARID3a^H^ naïve B cells are presented.](nihms826709f5){#F5}

![Monoclonal antibodies generated from ARID3a^H^ naïve B cells were not preferentially autoreactive compared to those generated from ARID3a^N^ naïve B cells. (**A**) Representative staining of nuclear antigens bound by positive control (top left), negative control (bottom left), two ARID3a^H^ (middle panel), or two ARID3a^N^ (right panel) monoclonal antibodies are shown. (**B**) Pie charts indicate percentages of ANA^+^ antibodies generated from ARID3a^N^ (n = 6/16, 38%) naïve B cells and ARID3a^H^ naïve B cells (n = 4/15, 27%).](nihms826709f6){#F6}

![ARID3a^H^ ANA^+^ monoclonal antibodies showed an increase in polyreactivity compared with ARID3a^N^ ANA^+^ antibodies. ANA^+^ monoclonal antibody specificities were tested against various nuclear antigens in SLE or other connective tissue diseases (Scl-70 and Jo-1), using INNO-LIA test strips. Test strips show binding reactivity compared to the positive control (**C**) shown in the first lane. Bands with more than one antigen are considered polyreactive.](nihms826709f7){#F7}

###### 

IgH gene origins.

  Sequence ID   V Gene Origin            D Gene Origin   J Gene Origin
  ------------- ------------------------ --------------- ---------------
  ARID3a^N^                                              
                                                         
  a03           IGHV1-69, or IGHV1-69D   IGHD2-15        IGHJ6
  a04           IGHV4-39                 IGHD3-10        IGHJ3
  a06           IGHV3-30                 IGHD1-26        IGHJ6
  b01           IGHV3-64D                IGHD4-17        IGHJ4
  b05           IGHV3-11                 IGHD3-10        IGHJ4
  c01           IGHV4-39                 IGHD3-10        IGHJ3
  c02           IGHV3-23                 IGHD3-22        IGHJ4
  c04           IGHV1-18                 IGHD2-15        IGHJ3
  d04           IGHV3-48                 IGHD3-22        IGHJ3
  e02           IGHV4-4                  IGHD2-15        IGHJ3
  e04           IGHV3-23                 IGHD6-13        IGHJ6
  e05           IGHV1-2                  IGHD6-13        IGHJ4
  e06           IGHV4-34                 IGHD1-1         IGHJ3
  f04           IGHV4-39                 IGHD3-10        IGHJ4
  f06           IGHV3-49                 IGHD3-10        IGHJ4
  g06           IGHV3-23                 IGHD5-24        IGHJ4
                                                         
  ARID3a^H^                                              
                                                         
  a03           IGHV3-23                 IGHD1-26        IGHJ4
  a06           IGHV3-30                 IGHD5-18        IGHJ4
  b04           IGHV3-48                 IGHD2-2         IGHJ4
  c02           IGHV1-2                  IGHD5-18        IGHJ4
  c03           IGHV4-4                  IGHD5-18        IGHJ6
  c06           IGHV3-23                 IGHD6-19        IGHJ4
  d02           IGHV4-59                 IGHD6-19        IGHJ4
  d03           IGHV3-23                 IGHD3-10        IGHJ4
  e02           IGHV3-21                 IGHD1-26        IGHJ4
  f03           IGHV3-15                 IGHD4-17        IGHJ4
  g01           IGHV3-7                  IGHD6-6         IGHJ4
  g03           IGHV1-69, or IGHV1-69D   IGHD3-10        IGHJ4
  g05           IGHV3-11                 IGHD2-15        IGHJ4
  g06           IGHV4-39                 IGHD3-10        IGHJ4
  h06           IGHV3-23                 IGHD6-19        IGHJ4

###### 

IgH CDR3 Summary.

  Sequence ID   Autoreactivity   CDR3 [\*](#TFN1){ref-type="table-fn"}   CDR3 Length
  ------------- ---------------- --------------------------------------- -------------
  ARID3a^N^                                                              
                                                                         
  a03                            A**R**VVGGYYYMDV                        12
  a04           X                A**RR**GSYEV**R**GVFGGAFDI              18
  a06           X                A**K**T**K**G**R**VGATINYYYYYMDV        20
  b01                            V**K**IPGTVTEDY                         11
  b05           X                AI**K**V**R**GVMY                       9
  c01                            A**RH**GGGSGSGTFDI                      14
  c02                            A**KH**P**H**TITMIVVAYYFDY              18
  c04                            A**R**SD**R**EGATSLSAFDI                16
  d04                            ASGGYYDSSGFDAFDI                        16
  e02           X                A**R**AYCSGGSCYSDAFDI                   17
  e04                            A**R**LSSSSWPYYYYYMDV                   17
  e05                            A**RR**AWGAAGNP                         11
  e06                            A**R**D**K**NAFDI                       9
  f04           X                AS**R**LWFGELSDY                        12
  f06                            **R**MV**R**GVIITTFDY                   13
  g06           X                V**K**DGPVAF                            8
                                                                         
  ARID3a^H^                                                              
                                                                         
  a03                            A**K**D**K**G**HH**ATTFFDY              14
  a06                            A**R**GAPDTAMVPFDY                      14
  b04                            A**R**WGVVPAAP**KR**GMDY                16
  c02           X                A**R**EVDTAMG**R**DY                    12
  c03                            A**R**D**KK**LSYYGMDV                   13
  c06           X                A**K**S**R**QWLFDY                      10
  d02                            A**R**EPLQAVAGYFDY                      14
  d03                            A**K**DQL**R**DYD**K**DY                12
  e02                            A**R**D**H**GTY**R**VGATT               13
  f03                            TTANGDYDFDY                             11
  g01           **X**            A**R**EFGTSSSSSGFFDY                    16
  g**03**                        ASGVTMV**R**GVMTTFDY                    16
  g05                            A**R**DDCSGGSCY**R**GGFDY               17
  g**06**       **X**            A**R**DLFWAPFDY                         11
  h06                            A**K**D**R**SSGLV**R**YFDY              14

Positively chared amino acids are in bold; Polyreactive ANAs are in bold.

###### 

BioPlex ANA panel antibody reactivities.

  Phenotype      H     H     H     H     N     N     N     N     N     N
  -------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  ID \#          c02   c06   g03   g06   a04   a06   b05   e02   f04   g06
  Sm             −     −     −     −     −     −     −     −     −     −
  Sm/RNP         −     −     \+    −     −     −     −     −     −     −
  RNP-A          −     −     −     −     −     −     −     −     −     −
  SSA/Ro         −     −     −     −     −     −     −     −     −     −
  SSB/La         −     −     −     −     −     −     −     −     −     −
  Centromere B   −     −     \+    −     −     −     −     −     −     −
  Scl-70         −     −     \+    −     −     −     −     −     −     −
  Jo-1           −     −     −     −     −     −     −     −     −     −
  Ribosomal P    −     −     \+    −     −     −     −     −     −     −
  Chromatin      −     −     \+    −     −     −     −     −     −     −
  dsDNA          −     −     −     −     −     −     −     −     −     −

H = ARID3a^H^; N = ARID3a^N^.
